Autonomic Nervous System Pharmacology | Sympathetic & Parasympathetic

Added:

Cotransmission and NANC Transmission: Beyond the Binary Model

While introductory ANS pharmacology focuses on a strict binary of adrenergic (sympathetic) and cholinergic (parasympathetic) transmission, this classical model is heavily modified by the discovery of cotransmission and Non-Adrenergic, Non-Cholinergic (NANC) transmission. Contrary to 'Dale's Principle'—which suggested each neuron releases only one transmitter—most autonomic nerves release multiple substances simultaneously. Alongside norepinephrine and acetylcholine, nerves co-release cotransmitters such as ATP, neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and nitric oxide. These NANC transmitters mediate significant physiological responses that are resistant to traditional adrenergic or cholinergic blocking agents. Furthermore, the modern view challenges the simplistic 'antagonistic' relationship (fight-or-flight vs. rest-and-digest) of the two divisions, demonstrating that they often operate synergistically or independently through complex local neuromodulation. Recognizing cotransmission is vital for understanding why traditional receptor-specific drugs sometimes produce incomplete clinical responses or unexpected side effects.

Basic anatomy of the nervous system, specifically the division between the Central Nervous System (CNS) and the Peripheral Nervous System (PNS).
The fundamental mechanism of chemical synaptic transmission, including neurotransmitter synthesis, vesicular release, and synaptic cleft dynamics.
Basic principles of pharmacodynamics, particularly how ligands (agonists and antagonists) interact with membrane-bound receptors.
The concept of homeostasis and the body's mechanisms for involuntary physiological regulation (e.g., heart rate, bronchodilation, digestion).
Specific therapeutic drug classes targeting the ANS, such as sympathomimetics, sympatholytics, parasympathomimetics, and anticholinergics.
Clinical applications of ANS-active drugs in treating major pathologies, including hypertension (beta-blockers), asthma (beta-2 agonists), and glaucoma.
The toxicological profiles and clinical presentations associated with ANS receptor overstimulation or blockade (e.g., cholinergic crisis vs. anticholinergic toxicity).
The specific G-protein coupled receptor (GPCR) intracellular signaling pathways (Gs, Gi, Gq) linked to each adrenergic and muscarinic receptor subtype.
1.8M views29.6Klikes8:15@SpeedPharmacologyOriginal Release: 2015-07-06

The autonomic nervous system regulates involuntary body functions through two opposing divisions: the sympathetic division (fight-or-flight response) arising from thoracic and lumbar spinal cord regions, which uses preganglionic cholinergic neurons and postganglionic adrenergic neurons to produce effects like pupil dilation, increased heart rate, and inhibited digestion; and the parasympathetic division (rest-and-digest response) arising from cranial nerves III, VII, IX, X and sacral regions S2-S4, which uses both preganglionic and postganglionic cholinergic neurons to produce opposite effects like pupil constriction, stimulated digestion, and slowed heart rate. Both divisions use nicotinic receptors at synapses between neurons, while effector organs receive signals through adrenergic receptors (for sympathetic) or muscarinic receptors (for parasympathetic), which are metabotropic receptors linked to G-proteins and intracellular second messengers.